First Tracks Biotherapeutics Secures $200 Million Private Placement
The company agreed to sell 6,106,870 common shares at $32.75 each to certain third-party investors, for expected gross proceeds of approximately $200 million. The placement is expected to close October 19, 2026.
First Tracks Biotherapeutics entered into a Securities Purchase Agreement with certain third-party investors to sell 6,106,870 shares of common stock at $32.75 per share, for expected gross proceeds of approximately $200 million. The private placement is expected to close on October 19, 2026, subje…